GBM Awareness Day is July 17. Join us in raising awareness all month long! Learn more.
A Feasibility Study to Evaluate the Safety of the TheraSphere Glioblastoma (GBM) Device in Patients With Recurrent GBM (FRONTIER)
Category (Adult, Pediatric):
AdultLocation:
New YorkPhase:
1Sponsor:
Boston ScientificDescription:
The FRONTIER study is a feasibility study assessing the use of TheraSphere GBM Y-90 Glass Microspheres in patients with recurrent GBM. The primary purpose of the study is to evaluate the safety of using this therapy in the brain.Last updated June 20, 2024
